The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer

BACKGROUND: Liquid biopsy (LB) can detect actionable genomic alterations in plasma circulating tumor circulating tumor DNA beyond tissue testing (TT) alone in advanced non-small cell lung cancer (NSCLC) patients. We estimated the cost-effectiveness of adding LB to TT in the Canadian healthcare syste...

Descripción completa

Detalles Bibliográficos
Autores principales: Ezeife, Doreen A., Spackman, Eldon, Juergens, Rosalyn A., Laskin, Janessa J., Agulnik, Jason S., Hao, Desiree, Laurie, Scott A., Law, Jennifer H., Le, Lisa W., Kiedrowski, Lesli A., Melosky, Barbara, Shepherd, Frances A., Cohen, Victor, Wheatley-Price, Paul, Vandermeer, Rachel, Li, Janice J., Fernandes, Roxanne, Shokoohi, Aria, Lanman, Richard B., Leighl, Natasha B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340413/
https://www.ncbi.nlm.nih.gov/pubmed/35923926
http://dx.doi.org/10.1177/17588359221112696

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340413/
https://www.ncbi.nlm.nih.gov/pubmed/35923926
http://dx.doi.org/10.1177/17588359221112696

Ejemplares similares